# Expanded Access for LJPC-501

> **NCT03245528** · — · APPROVED_FOR_MARKETING · sponsor: **La Jolla Pharmaceutical Company**

## Conditions studied

- Catecholamine Resistant Hypotension (CRH)
- Distributive Shock
- High Output Shock
- Sepsis
- Vasodilatory Shock

## Interventions

- **DRUG:** LJPC-501

## Key facts

- **NCT ID:** NCT03245528
- **Lead sponsor:** La Jolla Pharmaceutical Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2018-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03245528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03245528, "Expanded Access for LJPC-501". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03245528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*